Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019448 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00019448: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00019448 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019448, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. Combining vaccine therapy and interleukin-2 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy with or without interleukin-2 in treating patients with metastatic melanoma that has not responded to previous treatment.
Interventions
- DRUG gp100 antigen
- DRUG interleukin-2
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-09 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
What the finished NCT00019448 record still lists
NCT00019448 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which gp100 antigen is the first listed.
NCT00019448 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00019448 about?
NCT00019448 is a clinical study titled "Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma". RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. Combining vaccine therapy and interleukin-2 may kill more tumor cells. PURPOSE: Phase II trial to study the effectivenes...
What is the current status of trial NCT00019448?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-09. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00019448?
The interventions under investigation include: gp100 antigen (DRUG), interleukin-2 (DRUG).
Who is sponsoring clinical trial NCT00019448?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia